生検ガイダンスシステム市場：製品、用途、最終用途別-2025-2030年の世界予測

生検ガイダンスシステム市場は、2023年に14億4,000万米ドルと評価され、2024年には15億4,000万米ドルに達すると予測され、CAGR 7.34％で成長し、2030年には23億8,000万米ドルに達すると予測されています。

生検ガイダンスシステム市場には、診断目的で組織サンプルを採取する際の精度、安全性、効率を改善するために設計された技術や装置が含まれます。これらのシステムは、がんなどの異常を検出し、正確なターゲットを提供し、侵襲性を最小限に抑えるために極めて重要です。その必要性は、正確な診断を必要とするがんやその他の慢性疾患の有病率の上昇によって強調され、ヘルスケア施設に高度なガイダンス・システムの導入を促しています。用途は超音波、CT、MRIガイド下生検から定位手術、ロボット支援手術まで多岐にわたる。エンドユーザーは主に病院、診断センター、専門クリニックなどです。市場成長に影響を与える主な要因としては、イメージング技術の進歩、低侵襲手技に対する需要の高まり、ヘルスケア専門家の意識の高まりなどが挙げられます。しかし、機器コストの高さ、規制上のハードル、熟練者の不足、機器の標準化に関する問題などの課題が成長を阻害する可能性があります。医療インフラが拡大し、がん研究に対する政府資金が増加している新興市場には機会が豊富にあります。企業は、費用対効果が高く、持ち運びが可能で、使い勝手のよいシステムを革新するために研究開発に投資し、戦略的提携を通じて製品ポートフォリオを拡大し、使いやすさと普及を高めるためのトレーニングプログラムに注力することで、これらを活用することができます。限界という点では、手技中の副作用の可能性と厳しい規制遵守要件が大きな障壁となっています。技術革新が必要な分野としては、リアルタイムの画像解析のためのAI統合システムの開発、精度を高めるための機器間の無線通信の改善、1回限りの使用しかできない機器のための生分解性材料の使用などがあります。市場は急速な技術進化を遂げるダイナミックな市場だが、競争優位性を維持するためには、規制状況を慎重にナビゲートし、たゆまぬイノベーションを続けることが求められます。こうした状況を理解することを優先し、戦略的パートナーシップと技術的進歩を積極的に追求する企業は、持続的な成長を確保する上で最も有利な立場にあります。

市場力学：急速に進化する生検ガイダンスシステム市場の主要市場インサイトを公開

生検ガイダンスシステム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 診断処置を必要とするがんや慢性疾患の増加
  • 低侵襲生検治療への嗜好の高まり
  • 疾患の早期診断に向けた政府のキャンペーンや取り組み
• 市場抑制要因
  • 専門的トレーニングの必要性と生検システムの不正確さ
• 市場機会
  • 生検ガイダンスシステムの技術的進歩
  • 生検手技に対する有利な償還政策
• 市場の課題
  • 生検ガイダンスシステムに関連する技術的複雑性

ポーターのファイブフォース：生検ガイダンスシステム市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、生検ガイダンスシステム市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生検ガイダンスシステム市場における外部からの影響の把握

外部マクロ環境要因は、生検ガイダンスシステム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生検ガイダンスシステム市場における競合情勢の把握

生検ガイダンスシステム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生検ガイダンスシステム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生検ガイダンスシステム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生検ガイダンスシステム市場における成功への道筋を描く

生検ガイダンスシステム市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 診断処置を必要とするがんや慢性疾患の発生率の増加
    • 低侵襲生検治療への関心が高まる
    • 早期診断のための政府のキャンペーンと取り組み
  • 抑制要因
    • 専門的な訓練の必要性と生検システムの不正確さ
  • 機会
    • 生検誘導システムの技術的進歩
    • 生検処置に対する有利な償還方針
  • 課題
    • 生検ガイダンスシステムに関連する技術的な複雑さ
• 市場セグメンテーション分析
  • 製品：イメージング機能の向上を目指した超音波ガイド下生検への関心の高まり
  • アプリケーション：乳房生検のアプリケーションを改良し、精度を向上
  • 最終用途：診断アプリケーション用の高品質画像を可能にするために病院で生検ガイダンスシステムを採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 生検ガイダンスシステム市場：製品別

• MRIガイド下生検
• 定位ガイド下生検
• 超音波ガイド下生検

第7章 生検ガイダンスシステム市場：用途別

• 脳生検
• 乳房生検
• 肺
• 前立腺

第8章 生検ガイダンスシステム市場：最終用途別

• 診断センター
• 病院
• 調査・学術機関
• 専門クリニック

第9章 南北アメリカの生検ガイダンスシステム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の生検ガイダンスシステム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの生検ガイダンスシステム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDA、乳房生検用のMRI対応ロボットシステムを承認
  • ストライカー、頭蓋ガイダンスソフトウェアを搭載したQガイダンスを発売
  • GEヘルスケア、介入ガイダンスの能力強化のためIMACTIS買収契約を発表
• 戦略分析と提言

企業一覧

• Argon Medical Devices, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biobot Surgical Pte Ltd.
• Body Vision Medical Ltd.
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Group Incorporated
• Danaher Corporation
• Fujifilm Holdings Corporation
• GE Healthcare
• Hologic, Inc.
• IMS Giotto S.p.A
• Inomed Health Limited
• INRAD Inc.
• IZI Medical Products
• KOELIS
• Koninklijke Philips N.V.
• KPI Healthcare India pvt Ltd
• Mauna Kea Technologies
• Medtronic PLC
• Merit Medical Systems
• NeoDynamics AB
• Olympus Corporation
• Planmed Oy
• Siemens Healthineers AG
• STERYLAB S.r.l.
• Stryker Corporation
• Trivitron Healthcare

LIST OF FIGURES

• FIGURE 1. BIOPSY GUIDANCE SYSTEM MARKET RESEARCH PROCESS
• FIGURE 2. BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOPSY GUIDANCE SYSTEM MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOPSY GUIDANCE SYSTEM MARKET DYNAMICS
• TABLE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MRI GUIDED BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC GUIDED BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BRAIN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. CANADA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. INDIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. ITALY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. POLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. QATAR BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

The Biopsy Guidance System Market was valued at USD 1.44 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 7.34%, to USD 2.38 billion by 2030.

The biopsy guidance system market encompasses technologies and devices designed to improve the accuracy, safety, and efficiency of obtaining tissue samples for diagnostic purposes. These systems are crucial for detecting anomalies such as cancer, offering precise targeting and minimizing invasiveness. The necessity is underscored by the rising prevalence of cancer and other chronic diseases requiring accurate diagnostics, prompting healthcare facilities to adopt advanced guidance systems. Applications range from ultrasound, CT, MRI-guided biopsies to stereotactic and robotic-assisted procedures. End-users primarily include hospitals, diagnostic centers, and specialty clinics. Key factors influencing market growth include technological advancements in imaging, growing demand for minimally invasive procedures, and increasing awareness among healthcare professionals. However, challenges such as high equipment costs, regulatory hurdles, limited skilled personnel, and issues related to device standardization may impede growth. Opportunities abound in emerging markets with expanding healthcare infrastructure and increased government funding for cancer research. Companies can capitalize on these by investing in R&D to innovate cost-effective, portable, and user-friendly systems, expanding product portfolios through strategic collaborations, and focusing on training programs to enhance usability and adoption. In terms of limitations, the potential for adverse effects during procedures, coupled with stringent regulatory compliance requirements, pose significant barriers. Areas ripe for innovation include the development of AI-integrated systems for real-time image analysis, improved wireless communication between devices for enhanced accuracy, and the use of biodegradable materials for one-time use instruments. The market is dynamic with rapid technological evolution, yet it demands careful navigation through regulatory landscapes and persistent innovation to maintain competitive advantage. Businesses that prioritize understanding these landscapes and actively pursue strategic partnerships and technological advancements are best positioned to secure sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopsy Guidance System Market

The Biopsy Guidance System Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of cancer and chronic diseases requiring diagnostic procedures
  • Increasing preference for minimally invasive biopsy treatments
  • Government campaigns and initiatives for early disease diagnosis
• Market Restraints
  • Need for specialized training and inaccuracy of biopsy systems
• Market Opportunities
  • Technological advancements in biopsy guidance systems
  • Favorable reimbursement policies for biopsy procedures
• Market Challenges
  • Technical complexities associated with biopsy guidance system

Porter's Five Forces: A Strategic Tool for Navigating the Biopsy Guidance System Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopsy Guidance System Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopsy Guidance System Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopsy Guidance System Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopsy Guidance System Market

A detailed market share analysis in the Biopsy Guidance System Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopsy Guidance System Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopsy Guidance System Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biopsy Guidance System Market

A strategic analysis of the Biopsy Guidance System Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopsy Guidance System Market, highlighting leading vendors and their innovative profiles. These include Argon Medical Devices, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biobot Surgical Pte Ltd., Body Vision Medical Ltd., Boston Scientific Corporation, Cardinal Health, Inc., Cook Group Incorporated, Danaher Corporation, Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., IMS Giotto S.p.A, Inomed Health Limited, INRAD Inc., IZI Medical Products, KOELIS, Koninklijke Philips N.V., KPI Healthcare India pvt Ltd, Mauna Kea Technologies, Medtronic PLC, Merit Medical Systems, NeoDynamics AB, Olympus Corporation, Planmed Oy, Siemens Healthineers AG, STERYLAB S.r.l., Stryker Corporation, and Trivitron Healthcare.

Market Segmentation & Coverage

This research report categorizes the Biopsy Guidance System Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across MRI Guided Biopsy, Stereotactic Guided Biopsy, and Ultrasound Guided Biopsy.
• Based on Application, market is studied across Brain Biopsy, Breast Biopsy, Lungs, and Prostate.
• Based on End-Use, market is studied across Diagnostic Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of cancer and chronic diseases requiring diagnostic procedures
    • 5.1.1.2. Increasing preference for minimally invasive biopsy treatments
    • 5.1.1.3. Government campaigns and initiatives for early disease diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Need for specialized training and inaccuracy of biopsy systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in biopsy guidance systems
    • 5.1.3.2. Favorable reimbursement policies for biopsy procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Technical complexities associated with biopsy guidance system
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing inclination towards ultrasound guided biopsy for improved imaging capabilities
  • 5.2.2. Application: Improved applications for breast biopsies for enhanced accuracy
  • 5.2.3. End-Use: Adoption of biopsy guidance systems in hospitals to enable high-quality imaging for diagnostic applications
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biopsy Guidance System Market, by Product

• 6.1. Introduction
• 6.2. MRI Guided Biopsy
• 6.3. Stereotactic Guided Biopsy
• 6.4. Ultrasound Guided Biopsy

7. Biopsy Guidance System Market, by Application

• 7.1. Introduction
• 7.2. Brain Biopsy
• 7.3. Breast Biopsy
• 7.4. Lungs
• 7.5. Prostate

8. Biopsy Guidance System Market, by End-Use

• 8.1. Introduction
• 8.2. Diagnostic Centers
• 8.3. Hospitals
• 8.4. Research & Academic Institutes
• 8.5. Specialty Clinics

9. Americas Biopsy Guidance System Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Biopsy Guidance System Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Biopsy Guidance System Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Clears MRI-Compatible Robotics System for Breast Biopsy
  • 12.3.2. Stryker Launches Q Guidance with Cranial Guidance Software
  • 12.3.3. GE HealthCare Announces Agreement to Acquire IMACTIS to Strengthen Capabilities in Interventional Guidance
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Argon Medical Devices, Inc.
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Biobot Surgical Pte Ltd.
• 5. Body Vision Medical Ltd.
• 6. Boston Scientific Corporation
• 7. Cardinal Health, Inc.
• 8. Cook Group Incorporated
• 9. Danaher Corporation
• 10. Fujifilm Holdings Corporation
• 11. GE Healthcare
• 12. Hologic, Inc.
• 13. IMS Giotto S.p.A
• 14. Inomed Health Limited
• 15. INRAD Inc.
• 16. IZI Medical Products
• 17. KOELIS
• 18. Koninklijke Philips N.V.
• 19. KPI Healthcare India pvt Ltd
• 20. Mauna Kea Technologies
• 21. Medtronic PLC
• 22. Merit Medical Systems
• 23. NeoDynamics AB
• 24. Olympus Corporation
• 25. Planmed Oy
• 26. Siemens Healthineers AG
• 27. STERYLAB S.r.l.
• 28. Stryker Corporation
• 29. Trivitron Healthcare